2022 proved to be a 12 months the place the continuation of all issues COVID-19 performed an essential function by a lot of the 12 months. With discussions round vaccines, Lengthy COVID, and whether or not it might change into endemic or episodic, the virus dominated a lot of the information in infectious illness.
Different ID matters reminiscent of antimicrobial resistance and C difficile additionally proved to be essential matters folks wished to be taught extra about.
Listed under are a few of our hottest video interviews from this 12 months.
The Potential Advantages of the Novavax COVID-19 Vaccine
When the corporate submitted its knowledge to the federal regulatory authorities for an Emergency Use Authorization of its COVID-19 vaccine, NVX-CoV2373, again in February, William Schaffner,MD, medical director of the Nationwide Basis for Infectious Ailments (NFID) and Donald Alcendor, PhD, assistant professor of Most cancers Biology Meharry Medical Faculty, supplied some insights and perspective on the vaccine.
New “Lengthy Covid” Therapy Seems to be to Enhance Affected person Feeling and Operate
Axcella Therapeutics chief medical officer Margaret Koziel, MD, mentioned the stage 2a medical trial for his or her novel lengthy covid therapy.
Constructing Momentum for the Pasteur Act
Amanda Jezek, senior vp of public coverage and authorities relations at IDSA, supplied some insights on the inroads being made in Congress for this antimicrobial resistance laws.
COVID-19 Will ‘Not Grow to be Endemic However Episodic’
Robert Gottlieb, MD, PhD, FACC, Baylor Coronary heart and Vascular Hospital, foresaw the opportunity of the virus not turning into endemic however episodic.
Wanting Past C difficile: The Potential of the Intestine Microbiome
Elizabeth Garner, MD, speculated the FDA approval of RBX2660 for recurrent C difficile an infection will pave the best way for extra restorative microbiome therapies.
